miRNAs in bone metastasis

References

• Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27(3):165–176.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 2012;31(3–4):569–578.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;360(16):1655–1664.
   Web of Science ®Google Scholar
• Eichhorn SW, Guo H, McGeary SE, et al. mRNA destabilization is the dominant effect of mammalian microRNAs by the time substantial repression ensues. Mol Cell. 2014;56(1):104–115.
   PubMed Web of Science ®Google Scholar
• Lian JB, Stein GS, Van WAJ, et al. MicroRNA control of bone formation and homeostasis. Nat Rev Endocrinol. 2012;8(4):212–227.
   PubMed Web of Science ®Google Scholar
• Kapinas K, Delany AM. MicroRNA biogenesis and regulation of bone remodeling. Arthritis Res Ther. 2011;13(3):220.
   PubMed Web of Science ®Google Scholar
• Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866.
   PubMed Web of Science ®Google Scholar
• Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. 2011;13(1):27–38.
   PubMed Web of Science ®Google Scholar
• Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003;423(6937):349–355.
   PubMed Web of Science ®Google Scholar
• Akiyama H, Chaboissier MC, Schedl MJF. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16(21):2813–2828.
   PubMed Web of Science ®Google Scholar
• Komori T, Yagi H, Nomura S, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89(5):755–764.
   PubMed Web of Science ®Google Scholar
• Otto F, Thornell AP, Crompton T, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. Cell. 1997;89(5):765–771.
   PubMed Web of Science ®Google Scholar
• Nakashima K, Zhou X, Kunkel G, et al. The novel zinc finger-containing transcription factor Osterix is required for osteoblast differentiation and bone formation. Cell. 2002;108(1):17–29.
   PubMed Web of Science ®Google Scholar
• Zhou X, Zhang Z, Feng JQ, et al. Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice. Proc Natl Acad Sci USA. 2010;107(29):12919–12924.
   PubMed Web of Science ®Google Scholar
• Yang X, Matsuda K, Bialek P, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: implication for Coffin-Lowry syndrome. Cell. 2004;117(3):387–398.
   PubMed Web of Science ®Google Scholar
• Xiao G, Jiang D, Ge C, et al. Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem. 2005;280(35):30689–30696.
   PubMed Web of Science ®Google Scholar
• Atesok KI, Alman BA, Schemitsch EH, et al. Osteoid osteoma and osteoblastoma. J Am Acad Orthop Surg. 2011;19(11):678–689.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–1508.
   PubMed Web of Science ®Google Scholar
• Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638–649.
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi N, Udagawa N, et al. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20(3):345–357.
   PubMed Web of Science ®Google Scholar
• Boyce BF, Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9(Suppl 1):S1.
   PubMed Web of Science ®Google Scholar
• Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229–238.
   PubMed Web of Science ®Google Scholar
• Ibrahim T, Flamini E, Mercatali L, et al. Pathogenesis of osteoblastic bone metastases from prostate cancer. Cancer. 2010;116(6):1406–1418.
   PubMed Web of Science ®Google Scholar
• Chen YC, Sosnoski DM, Mastro AM. Breast cancer metastasis to the bone: mechanisms of bone loss. Breast Cancer Res. 2010;12(6):215.
   PubMed Web of Science ®Google Scholar
• Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem. 2010;109(2):283–291.
   PubMed Web of Science ®Google Scholar
• Theriault RL, Theriault RL. Biology of bone metastases. Cancer Control. 2012;19(2):92–101.
   PubMed Web of Science ®Google Scholar
• Boras-Granic K, Wysolmerski JJ. PTHrP and breast cancer: more than hypercalcemia and bone metastases. Breast Cancer Res. 2012;14(2):307.
   PubMed Web of Science ®Google Scholar
• Powell GJ, Southby J, Danks JA, et al. Localization of parathyroid hormone-related protein in breast cancer metastases: increased incidence in bone compared with other sites. Cancer Res. 1991;51(11):3059–3061.
   PubMed Web of Science ®Google Scholar
• Takagaki K, Takashima T, Onoda N, et al. Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients. Exp Ther Med. 2012;3(6):963–968.
   PubMed Web of Science ®Google Scholar
• Pavlovic M, Arnal-Estapé A, Rojo F, et al. Enhanced MAF oncogene expression and breast cancer bone metastasis. J Natl Cancer Inst. 2015;107(12):djv256.
   PubMedGoogle Scholar
• Soki FN, Park SI, McCauley LK. The multifaceted actions of PTHrP in skeletal metastasis. Futur Oncol. 2012;8(7):803–817.
   PubMed Web of Science ®Google Scholar
• Korpal M, Yan J, Lu X, et al. Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med. 2009;15(8):960–966.
   PubMed Web of Science ®Google Scholar
• Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem. 2004;91(4):718–729.
   PubMed Web of Science ®Google Scholar
• Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer. 2000;88(12 Suppl):2892–2898.
   PubMedGoogle Scholar
• Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999;103(2):197–206.
   PubMed Web of Science ®Google Scholar
• Dunn LK, Mohammad KS, Fournier PGJ, et al. Hypoxia and TGF-β drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One. 2009;4(9):e6896.
   PubMed Web of Science ®Google Scholar
• Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003;3(6):537–549.
   PubMed Web of Science ®Google Scholar
• Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem. 2003;88(4):660–672.
   PubMed Web of Science ®Google Scholar
• Fong YC, Maa MC, Tsai FJ, et al. Osteoblast-derived TGF-beta1 stimulates IL-8 release through AP-1 and NF-kappaB in human cancer cells. J Bone Miner Res. 2008;23(6):961–970.
   PubMed Web of Science ®Google Scholar
• Sethi N, Dai X, Winter CG, et al. Tumor-derived jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 2011;19(2):192–205.
   PubMed Web of Science ®Google Scholar
• Birkedal-Hansen H. Catabolism and turnover of collagens: collagenases. Methods Enzymol. 1987;144:140–171.
   PubMed Web of Science ®Google Scholar
• Lynch CC, Hikosaka A, Acuff HB, et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell. 2005;7(5):485–496.
   PubMed Web of Science ®Google Scholar
• Lu X, Wang Q, Hu G, et al. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev. 2009;23(16):1882–1894.
   PubMed Web of Science ®Google Scholar
• Chinni SR, Sivalogan S, Dong Z, et al. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate. 2006;66(1):32–48.
   PubMed Web of Science ®Google Scholar
• Sun YX, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res. 2005;20(2):318–329.
   PubMed Web of Science ®Google Scholar
• Sun YX, Fang M, Wang J, et al. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate. 2007;67(1):61–73.
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438(7069):820–827.
   PubMed Web of Science ®Google Scholar
• Erler JT, Bennewith KL, Nicolau M, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature. 2006;440(7088):1222–1226.
   PubMed Web of Science ®Google Scholar
• Erler JT, Bennewith KL, Cox TR, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell. 2009;15(1):35–44.
   PubMed Web of Science ®Google Scholar
• Cox TR, Rumney RM, Schoof EM, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106–110.
   PubMed Web of Science ®Google Scholar
• Kelly T, Suva LJ, Huang Y, et al. Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res. 2005;65(13):5778–5784.
   PubMed Web of Science ®Google Scholar
• Anborgh PH, Mutrie JC, Tuck AB, et al. Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med. 2010;14(8):2037–2044.
   PubMed Web of Science ®Google Scholar
• Pazolli E, Luo X, Brehm S, et al. Senescent stromal-derived osteopontin promotes preneoplastic cell growth. Cancer Res. 2009;69(3):1230–1239.
   PubMed Web of Science ®Google Scholar
• McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 2008;133(6):994–1005.
   PubMed Web of Science ®Google Scholar
• Brenner S, Whiting-Theobald N, Kawai T, et al. CXCR4-transgene expression significantly improves marrow engraftment of cultured hematopoietic stem cells. Stem Cells. 2004;22(7):1128–1133.
   PubMed Web of Science ®Google Scholar
• Christopher MJ, Liu F, Hilton MJ, et al. Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood. 2009;114(7):1331–1339.
   PubMed Web of Science ®Google Scholar
• Stier S, Ko Y, Forkert R, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med. 2005;201(11):1781–1791.
   PubMed Web of Science ®Google Scholar
• Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature. 2003;425(6960):841–846.
   PubMed Web of Science ®Google Scholar
• Méndez-Ferrer S, Michurina TV, Ferraro F, et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010;466(7308):829–834.
   PubMed Web of Science ®Google Scholar
• Westbrook JA, Cairns DA, Peng J, et al. CAPG and GIPC1 : breast cancer biomarkers for bone metastasis development and treatment. J Natl Cancer Inst. 2016;108:1–10.
   Google Scholar
• Savci-Heijink CD, Halfwerk H, Koster J, et al. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016;156(2):249–259.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Alvarez-Garcia I, Miska EA. MicroRNA functions in animal development and human disease. Development. 2005;132(21):4653–4662.
   PubMed Web of Science ®Google Scholar
• Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010;11(4):252–263.
   PubMed Web of Science ®Google Scholar
• Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–838.
   PubMed Web of Science ®Google Scholar
• Volinia S, Calin GA, Liu CG, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Nat Acad Sci USA. 2006;103(7):2257–2261.
   PubMed Web of Science ®Google Scholar
• Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–7070.
   PubMed Web of Science ®Google Scholar
• Ota D, Mimori K, Yokobori T, et al. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol. 2011;38(4):955–962.
   PubMed Web of Science ®Google Scholar
• Selth LA, Townley SL, Bert AG, et al. Circulating microRNAs predict biochemical recurrence in prostate cancer patients. Br J Cancer. 2013;109(3):641–650.
   PubMed Web of Science ®Google Scholar
• Gong C, Yao Y, Wang Y, et al. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem. 2011;286(21):19127–19137.
   PubMed Web of Science ®Google Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–688.
   PubMed Web of Science ®Google Scholar
• Yang J, Mani SA, Weinberg RA. Exploring a new twist on tumor metastasis. Cancer Res. 2006;66(9):4549–4552.
   PubMed Web of Science ®Google Scholar
• Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008;10(2):202–210.
   PubMed Web of Science ®Google Scholar
• Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601.
   PubMed Web of Science ®Google Scholar
• Sugatani T, Hruska KA. Impaired micro-RNA pathways diminish osteoclast differentiation and function. J Biol Chem. 2009;284(7):4667–4678.
   PubMed Web of Science ®Google Scholar
• Mizoguchi F, Izu Y, Hayata T, et al. Osteoclast-specific dicer gene deficiency suppresses osteoclastic bone resorption. J Cell Biochem. 2010;109(5):866–875.
   PubMed Web of Science ®Google Scholar
• Sugatani T, Hruska KA. MicroRNA-223 is a key factor in osteoclast differentiation. J Cell Biochem. 2007;101(4):996–999.
   PubMed Web of Science ®Google Scholar
• Luzi E, Marini F, Sala SC, et al. Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res. 2007;23(2):287–295.
   Web of Science ®Google Scholar
• Wang H, Xie Z, Hou T, et al. MiR-125b regulates the osteogenic differentiation of human mesenchymal stem cells by targeting BMPR1b. Cell Physiol Biochem. 2017;400038(30):530–542.
   Google Scholar
• Gong M, Ma J, Guillemette R, et al. miR-335 inhibits small cell lung cancer bone metastases via IGF-IR and RANKL pathways. Mol Cancer Res. 2014;12(1):101–110.
   PubMed Web of Science ®Google Scholar
• Tavazoie SF, Alarcón C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 2008;451(7175):147–152.
   PubMed Web of Science ®Google Scholar
• Png KJ, Halberg N, Yoshida M, et al. A microRNA regulon that mediates endothelial recruitment and metastasis by cancer cells. Nature. 2012;481(7380):190–194.
   Web of Science ®Google Scholar
• Png KJ, Yoshida M, Zhang XH, et al. MicroRNA-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. Genes Dev. 2011;25:226–231.
   PubMed Web of Science ®Google Scholar
• Krzeszinski JY, Wei W, Huynh H, et al. miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2. Nature. 2014;512(7515):431–435.
   PubMed Web of Science ®Google Scholar
• Chen W, Liu S, Chang Y, et al. MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. Oncotarget. 2014;6(1):441–457.
   Web of Science ®Google Scholar
• Sung SY, Liao CH, Wu HP, et al. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One. 2013;8(8):e71637.
   PubMed Web of Science ®Google Scholar
• Pollari S, Leivonen SK, Perälä M, et al. Identification of microRNAs inhibiting TGF-β-induced IL-11 production in bone metastatic breast cancer cells. PLoS One. 2012;7(5):e37361.
   PubMed Web of Science ®Google Scholar
• Valencia K, Luis-Ravelo D, Bovy N, et al. miRNA cargo within exosome-like vesicle transfer influences metastatic bone colonization. Mol Oncol. 2014;8(3):689–703.
   PubMed Web of Science ®Google Scholar
• Bae Y, Yang T, Zeng HC, et al. miRNA-34c regulates Notch signaling during bone development. Hum Mol Genet. 2012;21(13):2991–3000.
   PubMed Web of Science ®Google Scholar
• Xu M, Jin H, Xu CX, et al. MiR-34c inhibits osteosarcoma metastasis and chemoresistance. Med Oncol. 2014;31(6):972.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xie RL, Croce CM, et al. A program of microRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc Natl Acad Sci USA. 2011;108(24):9863–9868.
   PubMed Web of Science ®Google Scholar
• Engin F, Yao Z, Yang T, et al. Dimorphic effects of Notch signaling in bone homeostasis. Nat Med. 2008;14(3):299–305.
   PubMed Web of Science ®Google Scholar
• TaipaleenmäKi H, Browne G, Akech J, et al. Targeting of Runx2 by miR-135 and miR-203 impairs progression of breast cancer and metastatic bone disease. Cancer Res. 2015;75(7):1433–1444.
   PubMed Web of Science ®Google Scholar
• Saini S, Majid S, Yamamura S, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17(16):5287–5298.
   PubMed Web of Science ®Google Scholar
• Ell B, Mercatali L, Ibrahim T, et al. Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell. 2013;24(4):542–556.
   PubMed Web of Science ®Google Scholar
• Kuo PL, Liao SH, Hung JY, et al. MicroRNA-33a functions as a bone metastasis suppressor in lung cancer by targeting parathyroid hormone related protein. Biochim Biophys Acta. 2013;1830(6):3756–3766.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhu Y, Zhao M, et al. miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrinβ1 and matrix metalloproteinase2 (MMP2). PLoS One. 2013;8(8):e70192.
   PubMed Web of Science ®Google Scholar
• Lim PK, Bliss SA, Patel SA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011;71(5):1550–1560.
   PubMed Web of Science ®Google Scholar
• Mansi JL, Berger U, McDonnell T, et al. The fate of bone marrow micrometastases in patients with primary breast cancer. J Clin Oncol. 1989;7(4):445–449.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Yang P, Sun T, et al. miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol. 2013;15(3):284–294.
   PubMed Web of Science ®Google Scholar
• Kim MS, Day CJ, Morrison NA. MCP-1 is induced by receptor activator of nuclear factor-κB ligand, promotes human osteoclast fusion, and rescues granulocyte macrophage colony-stimulating factor suppression of osteoclast formation. J Biol Chem. 2005;280(16):16163–16169.
   PubMed Web of Science ®Google Scholar
• Hassan MQ, Maeda Y, Taipaleenmaki H, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem. 2012;287(50):42084–42092.
   PubMed Web of Science ®Google Scholar
• Ye ZB, Ma G, Zhao YH, et al. miR-429 inhibits migration and invasion of breast cancer cells in vitro. Int J Oncol. 2015;46(2):531–538.
   PubMed Web of Science ®Google Scholar
• Peng X, Guo W, Liu T, et al. Identification of miRs-143 and −145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One. 2011;6(5):e20341.
   PubMed Web of Science ®Google Scholar
• Li E, Zhang J, Yuan T, et al. MiR-143 suppresses osteogenic differentiation by targeting Osterix. Mol Cell Biochem. 2014;390(1–2):69–74.
   PubMed Web of Science ®Google Scholar
• Guo W, Ren D, Chen X, et al. HEF1 promotes epithelial mesenchymal transition and bone invasion in prostate cancer under the regulation of microRNA-145. J Cell Biochem. 2013;114(7):1606–1615.
   PubMed Web of Science ®Google Scholar
• Witwer KW. Circulating MicroRNA biomarker studies: pitfalls and potential solutions. Clin Chem. 2015;61(1):56–63.
   PubMed Web of Science ®Google Scholar
• Ono M, Kosaka N, Tominaga N, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal. 2014;7(332):ra63 LP–ra63.
   Web of Science ®Google Scholar
• Roccaro AM, Sacco A, Maiso P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013;123(4):1542–1555.
   PubMed Web of Science ®Google Scholar
• Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev. 1998;19(1):80–100.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Zhao ZN, Cheung JT, et al. Ibandronate promotes osteogenic differentiation of periodontal ligament stem cells by regulating the expression of microRNAs. Biochem Biophys Res Commun. 2011;404(1):127–132.
   PubMed Web of Science ®Google Scholar
• Fanale D, Amodeo V, Bazan V, et al. Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer? Oncotarget. 2016;7(20):29321–29332.
   PubMed Web of Science ®Google Scholar
• Fragni M, Bonini SA, Bettinsoli P, et al. The miR-21/PTEN/Akt signalling pathway is involved in the anti-tumoral effects of zoledronic acid in human breast cancer cell lines. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(5):529–538.
   PubMed Web of Science ®Google Scholar
• Fragni M, Bonini SA, Stabile A, et al. Inhibition of survivin is associated with zoledronic acid-induced apoptosis of prostate cancer cells. Anticancer Res. 2016;36(3):913–920.
   PubMed Web of Science ®Google Scholar
• Anastasilakis AD, Yavropoulou MP, Makras P, et al. Increased osteoclastogenesis in patients with vertebral factures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017;176(6):677–683.
   PubMed Web of Science ®Google Scholar
• Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–714.
   PubMed Web of Science ®Google Scholar